Patrick Thompson
Analyst · Mike Zaremski with BMO Capital
Great. Thank you, Steve. I'll start by walking through the key drivers of our Q1 results and then cover our Q2 outlook. As Steve mentioned, transaction value came in above the midpoint of our guidance range. Revenue was $310 million, above the high end of our guidance range, reflecting a favorable open marketplace mix shift driven by broader carrier participation in our marketplace. Adjusted EBITDA for the quarter was $31.4 million, up 7% year-over-year. Our efficient operating model and disciplined expense management allowed us to convert 64% of contribution to adjusted EBITDA. Excluding under 65 Health, our core business performance was very strong with year-over-year revenue and adjusted EBITDA each growing 28%. Turning to the balance sheet. We completed the refinancing of our credit facilities during the quarter. As detailed in the Form 8-K we filed with the SEC, we put in place a new $150 million senior secured term loan and a $60 million revolving credit facility, both maturing in March of 2031. The refinancing replaces our prior arrangements, extends our debt maturity profile meaningfully and provides enhanced financial flexibility. We drew modestly on the revolver in connection with closing, and we ended the quarter with $26.1 million in cash and $45 million undrawn on the revolver. On capital allocation, since the beginning of the year, we have repurchased approximately 2.6 million shares for $25 million, representing approximately 4% of the company. We remain committed and on track to complete the vast majority of the remaining $60 million of our $100 million authorization in 2026. Turning to Q2. We will be changing how we present guidance. We will be guiding to contribution and we will no longer report transaction values as we think contribution is a more relevant metric for investors evaluating the company's performance relative to our publicly traded peers. For Q2, we expect revenue of $290 million to $310 million, up approximately 19% year-over-year at the midpoint. Contribution of $45.5 million to $48.5 million, up approximately 18% year-over-year at the midpoint. Adjusted EBITDA of $28 million to $30.5 million, up approximately 19% year-over-year at the midpoint, including an approximately $2 million year-over-year decline in contribution from under 65 Health. Excluding under 65 Health, we expect contribution to increase by 25% and adjusted EBITDA to increase by 31% year-over-year. For Q2, we expect the health vertical to be approximately 1% of total revenue, as we made a strategic decision to limit under 65 Health open marketplace participation to carriers only, simplifying our operations. Looking at the remainder of 2026, we are entering a more normalized growth environment in P&C. Accordingly, we expect growth rates to moderate in the back half of 2026 as we lap increasingly strong prior year comparisons. For the year, we expect to generate $90 million to $100 million in free cash flow. Overall, we remain confident in the strength of our position and the long-term opportunity ahead. With that, operator, we are ready to take the first question.